Researchers at the University of British Columbia (UBC) in Vancouver, Canada report that semaglutide produces measurable reductions in bone mass and mechanical strength in diet-induced obese mice, with effects largely attributable to caloric restriction rather than direct GLP-1 receptor agonist activity on bone tissue, according to a study published June 19, 2026 in Cell Reports Medicine. The findings add to growing scrutiny of semaglutide side effects on bone and non-adipose tissues as the drug reaches tens of millions of users globally.
As GLP-1 obesity therapies reach tens of millions of patients, concerns have emerged about effects on lean tissue and bone health. The UBC study is among the first preclinical investigations to compare semaglutide-treated animals with a calorically matched control group.
Researchers used a diet-induced obesity mouse model and compared semaglutide-treated animals with pair-fed controls whose calorie intake was matched to the drug-treated group. Bone strength, femur mass, and markers of bone formation and resorption were assessed after four weeks of treatment and again following a six-week washout period.
Primary endpoints included femur dry weight, three-point bend biomechanical testing to assess bone strength and stiffness, and serum measurement of bone turnover markers — including CTX-1 for resorption, and bone alkaline phosphatase (BALP), osteocalcin, and procollagen type 1 N-propeptide (PINP) for formation activity.
Semaglutide-treated and pair-fed animals showed similar reductions in bone strength, stiffness, and femur mass relative to controls. Bone formation markers (BALP, osteocalcin and PINP) were reduced in both groups, while CTX-1 was unchanged, suggesting that weight loss suppresses bone formation rather than increasing bone resorption. The findings indicate that skeletal effects are primarily driven by caloric restriction and reduced mechanical loading rather than a direct drug-specific effect.